EP2139494
Lyfjasamsetningar sem innihalda dapaglíflósín-própýlenglýkól-hýdrat
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
21.3.2008EP published:
11.3.2020EP application number:
08732695.5
EP translation filed:
19.5.2020Grant published:
15.6.2020EPO information:
European Patent Register
Max expiry date:
20.3.2028Expiry date:
20.3.2027Next due date:
31.3.2027
Title:
PHARMACEUTICAL FORMULATIONS CONTAINING DAPAGLIFLOZIN PROPYLENE GLYCOL HYDRATE
Timeline
Today
21.3.2008EP application
11.3.2020EP Publication
19.5.2020Translation submitted
15.6.2020Registration published
20.3.2027Expires
Owner
Name:
AstraZeneca ABAddress:
151 85 Södertälje, SE
Inventor
Name:
BINDRA, Dilbir, S.Address:
New Brunswick, NJ 08903, US
Name:
DALI, Mandar, V.Address:
New Brunswick, NJ 08903, US
Name:
PARAB, Prakash, V.Address:
New Brunswick, NJ 08903, US
Name:
PATEL, Jatin, M.Address:
New Brunswick, NJ 08903, US
Name:
TAO, LiAddress:
New Brunswick, NJ 08903, US
Name:
TEJWANI, Ravindra, W.Address:
New Brunswick, NJ 08903, US
Name:
VATSARAJ, NipaAddress:
New Brunswick, NJ 08903, US
Name:
WU, YongmeiAddress:
New Brunswick, NJ 08903, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
896286 PDate:
22.3.2007Country:
US
Supplementary protection
SPC number:
SPC313
Classification
Categories:
A61K 31/70, A61K 9/16, A61K 9/20, A61P 3/10
Annual fees
Number
Paid
Expires
Payer
Number: 13
Paid: 8.5.2020
Expires: 20.3.2021
Payer: Árnason Faktor ehf.
Number: 14
Paid: 8.2.2021
Expires: 20.3.2022
Payer: Árnason Faktor ehf.
Number: 15
Paid: 8.2.2022
Expires: 20.3.2023
Payer: Árnason Faktor ehf.
Number: 16
Paid: 8.2.2023
Expires: 20.3.2024
Payer: Árnason Faktor ehf.
Number: 17
Paid: 14.2.2024
Expires: 20.3.2025
Payer: Árnason Faktor ehf.
Number: 18
Paid: 7.3.2025
Expires: 20.3.2026
Payer: Árnason Faktor ehf.
Number: 19
Paid: 20.3.2026
Expires: 20.3.2027
Payer: Árnason Faktor ehf.